Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 23.13% is in line with its 5-year average of 21.49%, near the high end of its 5-year range (16.44%–23.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.73% below its 12-month average of 23.30%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
23.13%
RETURN ON EQUITY (ROE) AVG TTM
23.30%
RETURN ON EQUITY (ROE) AVG 3Y
22.33%
RETURN ON EQUITY (ROE) AVG 5Y
21.49%
RETURN ON EQUITY (ROE) AVG 10Y
20.63%
RETURN ON EQUITY (ROE) AVG 15Y
19.80%
RETURN ON EQUITY (ROE) AVG 20Y
17.81%
CURRENT VS TTM AVG
-0.73%
CURRENT VS 3Y AVG
+3.58%
CURRENT VS 5Y AVG
+7.62%
CURRENT VS 10Y AVG
+12.11%
CURRENT VS 15Y AVG
+16.80%
CURRENT VS 20Y AVG
+29.87%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+72.87%
vs the sector median at left
ResMed Inc.
Market Cap
$32.43B
Return on Equity (ROE)
23.13%
TTM Avg
23.30%
3Y Avg
22.33%
5Y Avg
21.49%
Market Cap
$32.30B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$32.82B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$31.29B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$33.65B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$30.98B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$30.35B
Return on Equity (ROE)
4.43%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$29.57B
Return on Equity (ROE)
8.55%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$29.32B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $32.43B | 23.13% | 23.30% | 22.33% | 21.49% |
| Centene Corp. (CNC)vs › | $32.30B | -22.60% | -10.46% | -1.37% | 1.10% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.82B | 14.51% | 21.84% | 21.53% | 32.27% |
| Zoetis Inc. (ZTS)vs › | $31.29B | 83.10% | 66.19% | 56.82% | 52.60% |
| DexCom, Inc. (DXCM)vs › | $33.65B | 38.14% | 28.93% | 25.01% | 22.95% |
| Waters Corporation (WAT)vs › | $30.98B | 1.09% | 29.98% | 64.02% | 111.55% |
| Biogen Inc. (BIIB)vs › | $30.35B | 4.43% | 8.42% | 11.86% | 16.52% |
| Medline Inc. (MDLN)vs › | $29.57B | 8.55% | 9.02% | 4.86% | 4.86% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.32B | 59.67% | -187.43% | 134.89% | 51.69% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.06B | 7062.40% | -2178.82% | -341.14% | -117.12% |
ROE
23.1%
ROA
17.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 23.13% |
| 2025-06-30 | 23.47% |
| 2024-06-30 | 20.99% |
| 2023-06-30 | 21.73% |
| 2022-06-30 | 23.19% |
| 2021-06-30 | 16.44% |
| 2020-06-30 | 24.90% |
| 2019-06-30 | 19.52% |
| 2018-06-30 | 15.33% |
| 2017-06-30 | 17.46% |
| 2016-06-30 | 20.79% |
| 2015-06-30 | 22.23% |
| 2014-06-30 | 19.64% |
| 2013-06-30 | 19.07% |
| 2012-06-30 | 15.85% |
| 2011-06-30 | 13.11% |
| 2010-06-30 | 14.76% |
| 2009-06-30 | 13.13% |
| 2008-06-30 | 10.20% |
| 2007-06-30 | 7.12% |
| 2006-06-30 | 11.95% |
| 2005-06-30 | 13.67% |
| 2004-06-30 | 15.85% |
| 2003-06-30 | 15.96% |
| 2002-06-30 | 19.44% |
| 2001-06-30 | 11.59% |
| 2000-06-30 | 23.65% |
| 1999-06-30 | 22.49% |
| 1998-06-30 | 20.87% |
| 1997-06-30 | 16.82% |
